Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asciminib Roll-over Study for Long-term Safety in CML and ALL
NCT04877522Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Aug 2022
- Primary completion
- Aug 2030
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 29
01
Overview
A Phase 4 trial of asciminib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by Novartis. Started Aug 2022; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04877522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877522.